251 related articles for article (PubMed ID: 23811077)
1. Comparative immunochemical characteristics of botulinum neurotoxin type A and its associated proteins.
Bryant AM; Cai S; Singh BR
Toxicon; 2013 Sep; 72():126-32. PubMed ID: 23811077
[TBL] [Abstract][Full Text] [Related]
2. Immunological characterization of the subunits of type A botulinum neurotoxin and different components of its associated proteins.
Kukreja R; Chang TW; Cai S; Lindo P; Riding S; Zhou Y; Ravichandran E; Singh BR
Toxicon; 2009 May; 53(6):616-24. PubMed ID: 19673075
[TBL] [Abstract][Full Text] [Related]
3. Molecular composition and extinction coefficient of native botulinum neurotoxin complex produced by Clostridium botulinum hall A strain.
Bryant AM; Davis J; Cai S; Singh BR
Protein J; 2013 Feb; 32(2):106-17. PubMed ID: 23334849
[TBL] [Abstract][Full Text] [Related]
4. Enhancement of the endopeptidase activity of purified botulinum neurotoxins A and E by an isolated component of the native neurotoxin associated proteins.
Sharma SK; Singh BR
Biochemistry; 2004 Apr; 43(16):4791-8. PubMed ID: 15096048
[TBL] [Abstract][Full Text] [Related]
5. Comparative membrane channel size and activity of botulinum neurotoxins A and E.
Parikh S; Singh BR
Protein J; 2007 Jan; 26(1):19-28. PubMed ID: 17216364
[TBL] [Abstract][Full Text] [Related]
6. Immunological properties of Hn-33 purified from type A Clostridium botulinum.
Sharma SK; Singh BR
J Nat Toxins; 2000 Nov; 9(4):357-62. PubMed ID: 11126514
[TBL] [Abstract][Full Text] [Related]
7. Comparative role of neurotoxin-associated proteins in the structural stability and endopeptidase activity of botulinum neurotoxin complex types A and E.
Kukreja RV; Singh BR
Biochemistry; 2007 Dec; 46(49):14316-24. PubMed ID: 18004882
[TBL] [Abstract][Full Text] [Related]
8. A protease-resistant novel hemagglutinin purified from type A Clostridium botulinum.
Fu FN; Sharma SK; Singh BR
J Protein Chem; 1998 Jan; 17(1):53-60. PubMed ID: 9491928
[TBL] [Abstract][Full Text] [Related]
9. Characterization of the antibody response to the receptor binding domain of botulinum neurotoxin serotypes A and E.
Baldwin MR; Tepp WH; Pier CL; Bradshaw M; Ho M; Wilson BA; Fritz RB; Johnson EA; Barbieri JT
Infect Immun; 2005 Oct; 73(10):6998-7005. PubMed ID: 16177380
[TBL] [Abstract][Full Text] [Related]
10. Enhancement of the endopeptidase activity of botulinum neurotoxin by its associated proteins and dithiothreitol.
Cai S; Sarkar HK; Singh BR
Biochemistry; 1999 May; 38(21):6903-10. PubMed ID: 10346912
[TBL] [Abstract][Full Text] [Related]
11. A historical and proteomic analysis of botulinum neurotoxin type/G.
Terilli RR; Moura H; Woolfitt AR; Rees J; Schieltz DM; Barr JR
BMC Microbiol; 2011 Oct; 11():232. PubMed ID: 22008244
[TBL] [Abstract][Full Text] [Related]
12. Separation of the components of type A botulinum neurotoxin complex by electrophoresis.
Sharma SK; Ramzan MA; Singh BR
Toxicon; 2003 Mar; 41(3):321-31. PubMed ID: 12565755
[TBL] [Abstract][Full Text] [Related]
13. Expression and purification of neurotoxin-associated protein HA-33/A from Clostridium botulinum and evaluation of its antigenicity.
Sayadmanesh A; Ebrahimi F; Hajizade A; Rostamian M; Keshavarz H
Iran Biomed J; 2013; 17(4):165-70. PubMed ID: 23999711
[TBL] [Abstract][Full Text] [Related]
14. Hemagglutinin-33 of type A botulinum neurotoxin complex binds with synaptotagmin II.
Zhou Y; Foss S; Lindo P; Sarkar H; Singh BR
FEBS J; 2005 Jun; 272(11):2717-26. PubMed ID: 15943806
[TBL] [Abstract][Full Text] [Related]
15. Recombinant L-HN Fusion Antigen Derived from the L and HN Domains of Botulinum Neurotoxin B Stimulates a Protective Antibody Response Against Active Neurotoxin.
Li Z; Lu JS; Liu S; Wang R; Xu Q; Yu YZ; Yang ZX
Neurotox Res; 2021 Aug; 39(4):1044-1053. PubMed ID: 33616873
[TBL] [Abstract][Full Text] [Related]
16. The role of human serum albumin and neurotoxin associated proteins in the formulation of BoNT/A products.
Kutschenko A; Bigalke H; Wegner F; Wohlfarth K
Toxicon; 2019 Oct; 168():158-163. PubMed ID: 31323228
[TBL] [Abstract][Full Text] [Related]
17. Mapping of protective and cross-reactive domains of the type A neurotoxin of Clostridium botulinum.
Dertzbaugh MT; West MW
Vaccine; 1996 Nov; 14(16):1538-44. PubMed ID: 9014296
[TBL] [Abstract][Full Text] [Related]
18. High resolution crystal structures of Clostridium botulinum neurotoxin A3 and A4 binding domains.
Davies JR; Rees J; Liu SM; Acharya KR
J Struct Biol; 2018 May; 202(2):113-117. PubMed ID: 29288126
[TBL] [Abstract][Full Text] [Related]
19. Comparative study of immunological and structural properties of two recombinant vaccine candidates against botulinum neurotoxin type E.
Rostamian M; Mousavy SJ; Ebrahimi F; Ghadami SA; Sheibani N; Minaei ME; Arefpour Torabi MA
Iran Biomed J; 2012; 16(4):185-92. PubMed ID: 23183617
[TBL] [Abstract][Full Text] [Related]
20. Endopeptidase activities of botulinum neurotoxin type B complex, holotoxin, and light chain.
Wang HH; Riding S; Lindo P; Singh BR
Appl Environ Microbiol; 2010 Oct; 76(19):6658-63. PubMed ID: 20693440
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
